Arrowhead Pharmaceuticals to Present at Upcoming September Conferences
September 01 2016 - 7:30AM
Business Wire
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced
that the company will make presentations at the following upcoming
events.
The 23rd Annual NewsMakers in the Biotech
Industry – New York, September 9, 2016
September 9, 10:00 a.m. EDT – Christopher
Anzalone, Ph.D., Arrowhead president and CEO will deliver a
corporate presentation
7th Non-Coding RNA & RNAi Therapeutics Conference –
Boston, September 14-15, 2016
September 14, 4:30 p.m. EDT – Erik Bush,
Ph.D., Arrowhead director of extrahepatic targeting will deliver an
oral presentation titled, “Targeted delivery strategies using
Dynamic PolyconjugateTM (DPCTM)
technology”
2016 International HBV Meeting – Seoul, Korea, September
21-24, 2016
September 24, 8:30 a.m. KST – Zhao Xu, Ph.D.,
Arrowhead senior scientist will deliver an oral presentation
titled, “Functional HBsAg-encoding HBV fusion transcripts are
produced from integrated HBV DNA in chronically infected
chimpanzees - evidence from single molecule, real time (SMRT)
sequencing”
Copies of presentation materials and webcasts can be accessed on
the Events and Presentations page under the Investors section of
the Arrowhead website after each presentation is delivered.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat
intractable diseases by silencing the genes that cause them. Using
a broad portfolio of RNA chemistries and efficient modes of
delivery, Arrowhead therapies trigger the RNA interference
mechanism to induce rapid, deep, and durable knockdown of target
genes. RNA interference, or RNAi, is a mechanism present in living
cells that inhibits the expression of a specific gene, thereby
affecting the production of a specific protein. Arrowhead’s
RNAi-based therapeutics leverage this natural pathway of gene
silencing. The company’s pipeline includes ARC-520 and ARC-521 for
chronic hepatitis B virus infection, ARC-AAT for liver disease
associated with alpha-1 antitrypsin deficiency, ARC-F12 for
hereditary angioedema and thromboembolic disorders, ARC-LPA for
cardiovascular disease, and ARC-HIF2 for renal cell carcinoma.
For more information please visit www.arrowheadpharma.com, or
follow us on Twitter @ArrowheadPharma. To be added to the Company's
email list and receive news directly, please visit
http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation
Reform Act:
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our
actual results may differ materially and adversely from those
expressed in any forward-looking statements as a result of various
factors and uncertainties, including our ability to finance our
operations, the future success of our scientific studies, our
ability to successfully develop drug candidates, the timing for
starting and completing clinical trials, rapid technological change
in our markets, and the enforcement of our intellectual property
rights. Our most recent Annual Report on Form 10-K and subsequent
Quarterly Reports on Form 10-Q discuss some of the important risk
factors that may affect our business, results of operations and
financial condition. We assume no obligation to update or revise
forward-looking statements to reflect new events or
circumstances.
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead
Pharmaceuticals, Inc.
Source: Arrowhead Pharmaceuticals, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160901005260/en/
Arrowhead Pharmaceuticals, Inc.Vince Anzalone,
CFA626-304-3400ir@arrowheadpharma.comorInvestor
Relations:The Trout GroupChad
Rubin646-378-2947ir@arrowheadpharma.comorMedia:Russo
PartnersMatt Middleman,
M.D.212-845-4272matt.middleman@russopartnersllc.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2023 to Apr 2024